Journal article
Seroepidemiological study of Japanese encephalitis virus in Chiang Mai: Immunity and susceptibility 28 years after introduction of a vaccination programme
PLoS neglected tropical diseases, Vol.16(8), pp.e0010674-e0010674
08/01/2022
DOI: 10.1371/journal.pntd.0010674
PMCID: PMC9371339
PMID: 35913983
Abstract
Background
Thailand has introduced a nationwide vaccination against Japanese encephalitis virus (JEV) into National Immunization Programme since the 1990's. To improve the understanding of immunity and susceptibility of the population after 28 years of a vaccination programme, we conducted a JEV seroepidemiological study in a JEV-endemic area of Thailand.
Methods
An age-stratified, population-based, seroepidemiological study was conducted in Chiang Mai, Thailand-a northern Thai province where is an endemic area of Japanese encephalitis. Nine districts were chosen based on administrative definition: rural (n = 3); urban (n = 3); and peri-urban (n = 3). Within each district, eligible participants were randomly selected from 3 age groups: adolescents (10-20 years); adults (21-50 years); and older adults/elderly (>= 51 years) by computer randomization. Plaque reduction neutralization tests (PRNT50 and PRNT90) were performed to measure neutralizing antibodies to JEV. To account for the cross-reactivity of JEV and other flaviviruses, JEV seroprotection was defined according to age, previous history of JEV vaccination, and PRNT50/PRNT90 levels of study participants.
Results
Overall, 279 adolescents, 297 adults, and 297 older adults/elderly were enrolled from nine districts. Age-stratified, protocol-defined, cluster-adjusted JEV seroprotection rates were 61% (95% CI: 48-73%), 43% (95% CI: 31-57%), and 52% (95% CI: 37-67%) for adolescents, adults, and older adults/elderly, respectively. Living in peri-urban districts, having a history of prior dengue virus infection, and previously receiving mouse brain-derived JEV vaccine were significantly associated with seroprotection to JEV in adolescents. Older age and male sex were associated with seroprotection for adults; and only male sex was the associated factor for older adults/elderly (P <0.05).
Conclusions
Approximately half of population living in a JEV-endemic area demonstrated seroprotection to JEV. Ongoing nationwide surveillance on JEV seropepidemiology is an important strategy to understand the evolving population-level immunity to JEV, and to help formulating the appropriate recommendations on JE immunization.
Details
- Title: Subtitle
- Seroepidemiological study of Japanese encephalitis virus in Chiang Mai: Immunity and susceptibility 28 years after introduction of a vaccination programme
- Creators
- Tavitiya Sudjaritruk - Chiang Mai UniversityQuanhathai Kaewpoowat - Chiang Mai UniversityChanidapa Prasarakee - Chiang Mai UniversitySaowalak Sarachai - Chiang Mai UniversityAnne-Frieda Taurel - Sanofi, Vaccine Epidemiol & Modeling Dept, Singapore, SingaporeNatthanidnan Sricharoen - Chiang Mai UniversityPhatraporn Assawawongprom - Sanofi, Med Dept, Bangkok, ThailandJutamad Saheng - Chiang Mai UniversityRebecca Harris - Sanofi, Vaccine Epidemiol & Modeling Dept, Singapore, SingaporeJoshua Nealon - Sanofi, Vaccine Epidemiol & Modeling Dept, Singapore, SingaporeSutee Yoksan - Mahidol University
- Resource Type
- Journal article
- Publication Details
- PLoS neglected tropical diseases, Vol.16(8), pp.e0010674-e0010674
- DOI
- 10.1371/journal.pntd.0010674
- PMID
- 35913983
- PMCID
- PMC9371339
- NLM abbreviation
- PLoS Negl Trop Dis
- ISSN
- 1935-2735
- eISSN
- 1935-2735
- Publisher
- Public Library Science
- Number of pages
- 14
- Grant note
- JEC00030 / Sanofi
- Language
- English
- Date published
- 08/01/2022
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984359868202771
Metrics
5 Record Views